Novartis/Alcon: why the last 23% is worth the extra mile
This article was originally published in Scrip
Why is Novartis so doggedly pursuing full ownership of Alcon, an M&A transaction that rates among the most protracted the Swiss pharma group has ever undertaken?
You may also be interested in...
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.
COVID-19 business volatility continues to impact the medtech industry, but Royal Philips is targeting modest comparable sales growth for 2020 after posting quarterly growth of 10%.
Germany’s COVID-19 testing strategy now permits the use and reimbursement of coronavirus antigen tests.